The study focuses on Polycythemia Vera, a rare blood condition where the body makes too many red blood cells, causing the blood to become thicker than normal. The investigational medication being tested is called Sapablursen, which is given as a subcutaneous injection (a small needle placed under the skin). A matching placebo that looks the same but does not contain the active drug is also used. The purpose of the study is to compare how well Sapablursen works against the placebo in controlling the disease over a period of about eight months.
Participants are randomly assigned to receive either Sapablursen or the placebo, and neither the participants nor the study staff know which treatment is given (double‑blind). Throughout the study, regular blood tests are performed to measure the hematocrit level (the proportion of red blood cells in the blood). If the hematocrit rises above a certain level, a phlebotomy—a simple procedure where a small amount of blood is drawn to lower the count—may be needed. Researchers also ask participants to complete short questionnaires about fatigue and other symptoms to see how the treatment affects daily feeling. The trial lasts roughly 32 weeks, with visits scheduled at regular intervals to monitor safety, any side effects, and overall health.
Italy 